Novocure is a commercial-stage oncology company that develops and commercializes Tumor Treating Fields (TTFields), a non-invasive cancer therapy using electric fields to disrupt tumor cell division. It focuses on extending survival in aggressive forms of cancer, with commercialized products approved for glioblastoma and malignant pleural mesothelioma. The company has ongoing clinical trials for other solid tumors like lung, pancreatic, and ovarian cancer, aiming to expand the application of its innovative therapy.